argenx SE
argxNASDAQModerate RiskFcRn antibody technology
Market cap
Large cap
Cash position
$3.2B as of Q4 2025
48 months runway
Revenue status
early revenue
Pipeline assets
3 programs
What does argenx SE do?
argenx developed Vyvgart which lowers harmful antibody levels by blocking FcRn receptor. Approved for myasthenia gravis and tested for many autoimmune diseases. One of the most promising platform stories in biotech with over $3B cash. Key risk is competition from other FcRn drugs.
What to watch
CIDP Phase 3 data mid-2026
Vyvgart revenue growth
UCB competitive data
ITP results 2026
International launch
Pipeline
| Drug | Indication | Phase | Expected data | |
|---|---|---|---|---|
| Vyvgart | Generalized Myasthenia Gravis | Approved | — | ▼ |
| Vyvgart Hytrulo | CIDP | Phase 3 | — | ▼ |
| Empasiprubart | Kidney transplant rejection | Phase 2 | — | ▼ |
Investment thesis
Bull case
Dominant FcRn franchise with Vyvgart blockbuster. Same drug tested across CIDP ITP pemphigus myositis. Strong $3.2B cash. Peak sales exceed $8B. Platform validated across diseases.
Bear case
Intense FcRn competition. Label expansion failures possible. Pricing pressure. High valuation. Manufacturing complexity.
Key upcoming catalysts
CIDP Phase 3 ADHERE data
2026-06-01
ITP Phase 3 readout
2026-08-15
Pemphigus update
2026-04-20
Risk factors
FcRn competition
Label expansion failures
Pricing pushback
Manufacturing challenges
Market access
Comparable companies
Financial snapshot
Cash
$3.2B as of Q4 2025
Quarterly burn
Approaching breakeven
Cash runway
48 months
Revenue
early revenue
Institutional ownership
88%
Sponsored
Get premium argx analysis on Seeking AlphaAffiliate link — we may earn a commission at no cost to you